arrow
M

Marta Boffito

chelsea and westminster hospital
H指数:51
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stability of the HIV cascade of care throughout the COVID-19 pandemic in Europe: Results from the multinational EuroSIDA cohort study (2016–2022)

欧洲COVID-19大流行期间HIV治疗护理连续性稳定性:跨国EuroSIDA队列研究(2016–2022)的结果

2026-09-300
OAAI
Evaluation of the psychometric properties of the Episodic Disability Questionnaire (EDQ) among women living with HIV in the United Kingdom: A self-reported repeated measure study

评估英国女性艾滋病病毒感染者中《发作性残疾问卷》(EDQ)的心理测量特性:一项自我报告重复测量研究

2026-05-040
PRE
The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in HIV-associated Tuberculosis

利福平对HIV相关结核病患者中替诺福韦艾拉酚胺富马酸酯血浆及细胞内药代动力学的影响

2026-04-010
PRE
Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies

生活质量及治疗满意度:接受Bictegravir/Emtricitabine/Tenofovir Alafenamide转换治疗的HIV感染者——基于观察性队列研究的合并分析

2025-11-240
OAAI
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process

建立长效注射用卡博格韦和 rilpivirine 治疗的病毒学失败和停药共享定义(CONSENSUS-LAI 研究):一项国际调查和德尔菲过程

2025-08-040
OAAI
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions

优化卡博格韦尔联合 rilpivirine 长效疗法在 HIV 管理中的应用:证据、实施及未解决的问题

2025-07-012
OAAI